Evelo Biosciences Stock News

Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q4 2021 Results - Earnings Call Transcript

Short squeeze stocks to watch this week. The post Penny Stocks To Buy Now?

CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered

During the last session, Evelo Biosciences Inc. (NASDAQ:EVLO)’s traded shares were 0.59 million, with the beta value of the company hitting 1.67. At the end of the trading day, the stock’s price was $2.66, reflecting an intraday loss of -8.90% or -$0.26. The 52-week high for the EVLO share is $17.12, that puts it down … Is Evelo Biosciences Inc. (NASDAQ: EVLO) Still A Buy After sinking -12.79% Last Week? Read More »

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that Simba Gill, Ph.D., Chief Executive Officer of Evelo, will participate in a panel discussion titled “ GI/Microbiome ” at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9 th , 2022 at 10:30 a.m. ET.

Evelo Biosciences (EVLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Evelo Biosciences (EVLO) reported data from a post-treatment follow-up (Part B) of its phase 2 trial of EDP1815 in mild and moderate psoriasis which included durable and deeper…

-18/30 patients maintained a PASI-50 or greater response at 24 weeks post-treatment- -9/20 patients experienced a deepening of response from PASI-50 to at least PASI-75 during post-treatment period- -No flare or rebound observed following discontinuation of treatment- -Evelo to host KOL webcast to discuss these data, along with unmet need in psoriasis, on March 11, 2022 - CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ: EVLO ), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data from the post-treatment follow-up (Part B) of its Phase 2 trial of EDP1815 in mild and moderate psoriasis which included durable and deeper clinical responses. EDP1815 is an investigational oral biologic currently in development for the treatment of a broad range of inflammatory diseases, including clinical programs in psoriasis, atopic dermatitis, and COVID-19. "The totality of data from the EDP1815 Phase 2 trial, which includes these Part B results, and the previously reported clinical and cytokine biomarker improvements observed over the 16 week dosing period, support the potential of EDP1815 to address systemic inflammation and deliver long-lasting and clinically meaningful benefit to patients with psoriasis," said Duncan McHale, M.B.B.S., Ph.D., Chief Medical Officer of Evelo. "These data are encouraging and support our view that SINTAX medicines work with the immune system to resolve inflammation - and that these effects can persist after the drug is stopped.

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Evelo Biosciences (EVLO) said the first patient was dosed in a phase 2 trial of EDP1815 to treat patients with mild, moderate, and severe atopic dermatitis, also known…

Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Reporting data from a biomarker analysis of its Phase 2 trial for EDP1815 in patients with psoriasis, Evelo Biosciences (EVLO) said that there was a statistically significant reduction

Evelo Biosciences Inc (NASDAQ: EVLO ) has announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed EDP1815 in mild and moderate psoriasis. Treatment with EDP1815 led to a statistically significant reduction in the release of cytokines compared to placebo : IL-6 (p=0.0003), IL-8 (p=0.0007), and TNF (p=0.0037). The effect of EDP1815 was observed by … Full story available on Benzinga.com

Evelo Biosciences Inc EVLO has announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed EDP1815 in mild and moderate psoriasis. Get the Ins

CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ: EVLO ), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company''s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congress in Koloa, Hawaii. "The data presented today build on the substantial evidence accumulated through our clinical and preclinical work, deepening our understanding of the mechanism by which EDP1815 drives its clinical effects. They explain how an oral, gut-restricted SINTAX medicine can interact with the immune system in the gut, leading to systemic inflammation resolution without immunosuppression or concerning side-effects," said Douglas Maslin, M.Phil, M.B.